Suppr超能文献

关于2019冠状病毒病(COVID-19)传统医学治疗选择的叙述性文献综述。

A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19).

作者信息

Mirzaie Amir, Halaji Mehrdad, Dehkordi Farhad Safarpoor, Ranjbar Reza, Noorbazargan Hassan

机构信息

Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

出版信息

Complement Ther Clin Pract. 2020 Aug;40:101214. doi: 10.1016/j.ctcp.2020.101214. Epub 2020 Jun 17.

Abstract

Coronavirus disease 2019 (COVID-19) as a life-threatening disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is accounted as global public health concern. Treatment of COVID-19 is primarily supportive and the role of antiviral agents is yet to be established. However, there are no specific anti-COVID-19 drugs and vaccine until now. This review focuses on traditional medicine such as medicinal plant extracts as promising approaches against COVID-19. Chinese, Indian and Iranian traditional medicine, suggests some herbs for prevention, treatment and rehabilitation of the diseases including COVID-19. Although, inhibition of viral replication is considered as general mechanism of herbal extracts, however some studies demonstrated that traditional herbal extracts can interact with key viral proteins which are associated with virus virulence. Chinese, Indian and Iranian traditional medicine, suggests some herbs for prevention, treatment and rehabilitation of the diseases including COVID-19. However the beneficial effects of these traditional medicines and their clinical trials remained to be known. Herein, we reviewed the latest updates on traditional medicines proposed for treatment of COVID-19.

摘要

2019年冠状病毒病(COVID-19)作为一种危及生命的疾病,由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,这是一个全球公共卫生问题。COVID-19的治疗主要是支持性的,抗病毒药物的作用尚未确定。然而,到目前为止还没有特效的抗COVID-19药物和疫苗。本综述重点关注传统医学,如药用植物提取物,作为对抗COVID-19的有前景的方法。中国、印度和伊朗的传统医学提出了一些用于预防、治疗和康复包括COVID-19在内的疾病的草药。虽然抑制病毒复制被认为是草药提取物的一般机制,但一些研究表明,传统草药提取物可以与与病毒毒力相关的关键病毒蛋白相互作用。中国、印度和伊朗的传统医学提出了一些用于预防、治疗和康复包括COVID-19在内的疾病的草药。然而,这些传统药物的有益效果及其临床试验仍有待了解。在此,我们综述了用于治疗COVID-19的传统药物的最新进展。

相似文献

1
A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19).
Complement Ther Clin Pract. 2020 Aug;40:101214. doi: 10.1016/j.ctcp.2020.101214. Epub 2020 Jun 17.
2
Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective.
Int J Biol Sci. 2020 Mar 15;16(10):1708-1717. doi: 10.7150/ijbs.45538. eCollection 2020.
3
Databases for facilitating mechanistic investigations of traditional Chinese medicines against COVID-19.
Pharmacol Res. 2020 Sep;159:104989. doi: 10.1016/j.phrs.2020.104989. Epub 2020 Jun 2.
6
Herbal medicine for treatment of children diagnosed with COVID-19: A review of guidelines.
Complement Ther Clin Pract. 2020 May;39:101174. doi: 10.1016/j.ctcp.2020.101174. Epub 2020 Apr 12.
7
[Analysis of property and efficacy of traditional Chinese medicine in staging revention and treatment of coronavirus disease 2019].
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1253-1258. doi: 10.19540/j.cnki.cjcmm.20200225.501.
8
Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).
Pharmacol Res. 2020 Aug;158:104939. doi: 10.1016/j.phrs.2020.104939. Epub 2020 May 21.
9
[Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus].
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1263-1271. doi: 10.19540/j.cnki.cjcmm.20200219.501.
10
East meets West in COVID-19 therapeutics.
Pharmacol Res. 2020 Sep;159:105008. doi: 10.1016/j.phrs.2020.105008. Epub 2020 Jun 9.

引用本文的文献

1
Prunus amygdalus var. amara seed extract enhances the antileishmanial activity of miltefosine.
BMC Complement Med Ther. 2025 Jul 16;25(1):273. doi: 10.1186/s12906-025-04958-z.
4
COVID-19 and environment: a poignant reminder of sustainability in the new normal.
Environ Sustain (Singap). 2021;4(4):649-670. doi: 10.1007/s42398-021-00207-4. Epub 2021 Sep 24.
5
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
9
Whole-genome sequencing in medicinal plants: current progress and prospect.
Sci China Life Sci. 2024 Feb;67(2):258-273. doi: 10.1007/s11427-022-2375-y. Epub 2023 Oct 12.

本文引用的文献

1
Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury.
Natl Sci Rev. 2020 Jun;7(6):1003-1011. doi: 10.1093/nsr/nwaa037. Epub 2020 Mar 9.
2
Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review.
Iran J Public Health. 2020 Oct;49(Suppl 1):18-29. doi: 10.18502/ijph.v49iS1.3666.
3
An updated review of the association of host genetic factors with susceptibility and resistance to COVID-19.
J Cell Physiol. 2021 Jan;236(1):49-54. doi: 10.1002/jcp.29868. Epub 2020 Jun 15.
5
Traditional Chinese Medicine treatment of COVID-19.
Complement Ther Clin Pract. 2020 May;39:101165. doi: 10.1016/j.ctcp.2020.101165. Epub 2020 Apr 1.
7
Therapeutic strategies for critically ill patients with COVID-19.
Ann Intensive Care. 2020 Apr 20;10(1):45. doi: 10.1186/s13613-020-00661-z.
8
Real-time RT-PCR in COVID-19 detection: issues affecting the results.
Expert Rev Mol Diagn. 2020 May;20(5):453-454. doi: 10.1080/14737159.2020.1757437. Epub 2020 Apr 22.
9
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.
Trends Pharmacol Sci. 2020 Jun;41(6):363-382. doi: 10.1016/j.tips.2020.03.006. Epub 2020 Apr 9.
10
A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
Int J Mol Sci. 2020 Apr 10;21(7):2657. doi: 10.3390/ijms21072657.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验